Rhythm Pharmaceuticals, Inc. (RYTM)
After hours:
| Previous close | 40.98 |
| Open | 42.49 |
| Bid | 43.71 x 200 |
| Ask | 43.80 x 100 |
| Day's range | 41.87 - 43.99 |
| 52-week range | 15.50 - 52.57 |
| Volume | |
| Avg. volume | 575,614 |
| Market cap | 2.668B |
| Beta (5Y monthly) | 1.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.20 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 59.00 |
ZacksWill Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksEarnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline
Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlobeNewswireRhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
- Publication highlights administration of setmelanotide therapy resulted in a mean percent reduction in BMI of 15% at 16 weeks and 26% at one year of treatment - - Topline data from ongoing pivotal Phase 3 clinical trial in hypothalamic obesity on track for 2Q 2025 - BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendo
